Rosmaricine derivatives as potential antitumoral agents.
A group of N-(alkylaminoacyl)-O,O-dimethylrosmaricines was prepared and, together with a set of rosmaricine derivatives previously described by us, evaluated for activity against lymphocytic leukemia P 388. Only one compound exhibited a borderline activity, while all the others were inactive.